BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-horin S. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 2016;43:1293-9. [DOI: 10.1111/apt.13631] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Agrawal M, Dubinsky MC, Colombel J. Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out. Journal of Crohn's and Colitis 2020;14:1035-6. [DOI: 10.1093/ecco-jcc/jjaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Choy MC, De Cruz P. Letter: dose optimising infliximab in acute severe ulcerative colitis. Aliment Pharmacol Ther 2017;45:1169-70. [PMID: 28326583 DOI: 10.1111/apt.13980] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 144] [Cited by in F6Publishing: 117] [Article Influence: 28.8] [Reference Citation Analysis]
5 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kushkevych I, Martínková K, Vítězová M, Rittmann SKR. Intestinal Microbiota and Perspectives of the Use of Meta-Analysis for Comparison of Ulcerative Colitis Studies. J Clin Med 2021;10:462. [PMID: 33530381 DOI: 10.3390/jcm10030462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Sanchez-Hernandez JG, Rebollo N, Munoz F, Martin-Suarez A, Calvo MV. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. Ann Clin Biochem 2019;56:28-41. [PMID: 29807436 DOI: 10.1177/0004563218782286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2018;12:797-810. [DOI: 10.1080/17474124.2018.1494573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
10 Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, Walters TD, Griffiths AM. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis. J Crohns Colitis 2019;13:982-9. [PMID: 30715240 DOI: 10.1093/ecco-jcc/jjz019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
11 Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology 2018;113:890-8. [DOI: 10.1038/s41395-018-0073-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
12 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 deBruyn JCC, Jacobson K, El-Matary W, Wine E, Carroll MW, Goedhart C, Panaccione R, Wrobel IT, Huynh HQ. Early Serum Infliximab Levels in Pediatric Ulcerative Colitis. Front Pediatr 2021;9:668978. [PMID: 34395336 DOI: 10.3389/fped.2021.668978] [Reference Citation Analysis]
14 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
15 Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med 2021;10:5642. [PMID: 34884344 DOI: 10.3390/jcm10235642] [Reference Citation Analysis]
16 Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018;47:478-484. [PMID: 29210094 DOI: 10.1111/apt.14458] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
17 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Reference Citation Analysis]
18 Strik AS, Wang YC, Ruff LE, Yashar W, Messmer BT, Mould DR. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm? AAPS J 2018;20:99. [PMID: 30187153 DOI: 10.1208/s12248-018-0257-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
19 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Poullenot F, Nivet D, Paul S, Riviere P, Roblin X, Laharie D. Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis. Digestive and Liver Disease 2018;50:1100-3. [DOI: 10.1016/j.dld.2018.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017;23:1510-1515. [PMID: 28816757 DOI: 10.1097/mib.0000000000001231] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
22 Berends SE, Strik AS, Jansen JM, de Boer NK, van Egmond PS, Brandse JF, Mathôt RA, D’haens GR, Löwenberg M. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology 2019;54:700-6. [DOI: 10.1080/00365521.2019.1619828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
23 Ben-horin S, Ungar B, Roblin X. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply. Aliment Pharmacol Ther 2017;45:760-2. [DOI: 10.1111/apt.13932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
24 Roblin X, Riviere P, Flamant M, Veyrard P, Poullenot F, Paul S, Laharie D. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:1904-9. [DOI: 10.1093/ibd/izy069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
25 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 21] [Article Influence: 21.3] [Reference Citation Analysis]
26 Dai C, Jiang M, Sun MJ. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis. Dig Dis Sci 2019;64:1386-7. [PMID: 30830524 DOI: 10.1007/s10620-019-05531-8] [Reference Citation Analysis]
27 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
28 Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Reference Citation Analysis]
29 Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 2021. [PMID: 34388143 DOI: 10.14309/ajg.0000000000001396] [Reference Citation Analysis]
30 Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-horin S, Roblin X, Kopylov U. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohnʼs Disease Treated with Tumor Necrosis Factor Inhibitors: . Inflammatory Bowel Diseases 2017;23:1924-9. [DOI: 10.1097/mib.0000000000001220] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
31 Osterman MT, Lichtenstein GR. Infliximab vs Adalimumab for UC: Is There A Difference? Clin Gastroenterol Hepatol 2017;15:1197-9. [PMID: 28479503 DOI: 10.1016/j.cgh.2017.04.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 2017;13:1039-46. [PMID: 28876147 DOI: 10.1080/17425255.2017.1377180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
33 Strik AS, Löwenberg M, Mould DR, Berends SE, Ponsioen CI, van den Brande JMH, Jansen JM, Hoekman DR, Brandse JF, Duijvestein M, Gecse KB, de Vries A, Mathôt RA, D'Haens GR. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol 2021;56:145-54. [PMID: 33290108 DOI: 10.1080/00365521.2020.1856405] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
34 Jerger L, Hyams JS. Special considerations for biologic medications in pediatric ulcerative colitis. Expert Opin Biol Ther 2020;20:429-35. [PMID: 31652087 DOI: 10.1080/14712598.2020.1685492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
36 Moore H, Dolce P, Devas N, Baldassano R, Martinelli M. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis. United European Gastroenterol J 2020;8:425-35. [PMID: 32213038 DOI: 10.1177/2050640620912877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
38 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Bor R, Farkas K, Fábián A, Bálint A, Milassin Á, Rutka M, Matuz M, Nagy F, Szepes Z, Molnár T. Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. PLoS One 2017;12:e0172916. [PMID: 28362851 DOI: 10.1371/journal.pone.0172916] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
40 Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson JD, Arkir Z, Irving PM. Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterol 2017;8:189-95. [PMID: 28839908 DOI: 10.1136/flgastro-2016-100739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 2017; 152: 351-361. e5. [PMID: 27720840 DOI: 10.1053/j.gastro.2016.09.046] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 21.3] [Reference Citation Analysis]
42 Chaparro M, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-sánchez V, Marín-jiménez I, Barreiro-de Acosta M, Vera I, Martín-arranz MD, Hernández-breijo B, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Bermejo F, Beltrán B, Rodríguez Pescador A, Banales JM, Olivares D, Aguilar-melero P, Menchén L, Ferreiro-iglesias R, Blazquez Gomez I, Benítez García B, Guijarro LG, Marin A, Bernardo D, Gisbert JP. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease. European Journal of Gastroenterology & Hepatology 2020;32:588-96. [DOI: 10.1097/meg.0000000000001706] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
44 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
45 Fiske J, Conley T, Sebastian S, Subramanian S. Infliximab in acute severe colitis: getting the right dose. Frontline Gastroenterol 2020;11:427-9. [PMID: 33104078 DOI: 10.1136/flgastro-2020-101407] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017;153:835-857.e6. [PMID: 28774547 DOI: 10.1053/j.gastro.2017.07.031] [Cited by in Crossref: 149] [Cited by in F6Publishing: 124] [Article Influence: 29.8] [Reference Citation Analysis]
47 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
48 Bar-yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-horin S, Chowers Y, Ungar B. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018;47:212-8. [DOI: 10.1111/apt.14410] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
49 Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. Journal of Crohn's and Colitis 2018;12:662-9. [DOI: 10.1093/ecco-jcc/jjy028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
50 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
51 Samaan MA, Arkir Z, Ahmad T, Irving PM. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Expert Opin Biol Ther 2018;18:1271-9. [PMID: 30339466 DOI: 10.1080/14712598.2018.1537367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]